{
  "id": 16212416,
  "title": "Newamsterdam Pharma stock hits 52-week low at 19.57 USD",
  "url": "https://urgent.news/2026/10/23/newamsterdam-pharma-stock-hits-52-week-low-at-19-57-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-23T18:21:23.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/newamsterdam-pharma-stock-hits-52week-low-at-1957-usd-93CH-4970221"
  },
  "original_language": "en",
  "account": null,
  "summary": "NewAmsterdam Pharma's stock has hit its 52-week low at $19.57, a 44.92% decline over the past year and reflecting the challenges the company faces in the current market environment. Despite this downturn, the stock appears undervalued according to analyst price targets, which range from $38.02 to $59.29. Recent developments include the EU regulatory approval for NewAmsterdam Pharma's obicetrapib and ezetimibe fixed-dose combination, as well as Stifel's continued support for the company through a Buy rating and a price target of $50.00. CEO Michael H. Davidson's recent purchase of 10,000 shares also adds to the narrative of investor confidence.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}